Skip to content
2000
Volume 31, Issue 26
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The risk of illnesses is increasing in the modern era due to unhealthy and modern lifestyles. Research has shown that the most frequent acid-induced abrasion, which often occurs in the stomach and proximal duodenum, is gastric and peptic ulcer disease (PUD), which is a primary worldwide health concern. The deformity is characterized by denuded mucosa and spreads into the submucosa. Non-steroidal anti-inflammatory drugs (NSAIDs) and infections are two common offenders. In the past, it has been thought that dietary variables, stress, and an acidic hypersecretory state encourage mucosal disruption in peptic acid disease patients. Peptic ulcers continue to be a significant health issue because of their potential for substantial consequences, including bleeding, blockage, and perforation, even with advancements in detection and treatment. This review discusses current screening methods for peptic ulcers and the challenges in diagnosis and treatment, emphasizing the need for precise diagnosis and more effective therapies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128310979240828102727
2024-09-24
2025-10-23

  • From This Site

    /content/journals/cpd/10.2174/0113816128310979240828102727
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. NarayananM. ReddyK.M. MarsicanoE. Peptic ulcer disease and Helicobacter pylori infection.Mo. Med.2018115321922430228726
     [Google Scholar]
  2. YeoS.H. YangC.H. Peptic ulcer disease associated with Helicobacter pylori infection.Korean J. Gastroenterol.201667628929910.4166/kjg.2016.67.6.28927312829
     [Google Scholar]
  3. PéricoL.L. Emílio-SilvaM.T. OharaR. RodriguesV.P. BuenoG. Barbosa-FilhoJ.M. RochaL.R.M. BatistaL.M. Hiruma-LimaC.A. Systematic analysis of monoterpenes: Advances and challenges in the treatment of peptic ulcer diseases.Biomolecules202010226510.3390/biom1002026532050614
     [Google Scholar]
  4. ChuahS.K. WuD.C. SuzukiH. GohK.L. KaoJ. RenJ.L. Peptic ulcer diseases: Genetics, mechanism, and therapies.BioMed Res. Int.201420141410.1155/2014/89834925610875
     [Google Scholar]
  5. ZaliM.R. Facing resistance of H. pylori infection.Gastroenterol. Hepatol. Bed Bench20114131124834148
     [Google Scholar]
  6. FashnerJ. GituA.C. Diagnosis and treatment of peptic ulcer disease and H. pylori infection.Am. Fam. Physician201591423624225955624
     [Google Scholar]
  7. SousaC. FerreiraR. AzevedoN.F. OleastroM. AzeredoJ. FigueiredoC. MeloL.D.R. Helicobacter pylori infection: From standard to alternative treatment strategies.Crit. Rev. Microbiol.202248337639610.1080/1040841X.2021.197564334569892
     [Google Scholar]
  8. SrisuphanuntM. WilairatanaP. KooltheatN. DuangchanT. KatzenmeierG. RoseJ.B. Molecular mechanisms of antibiotic resistance and novel treatment strategies for Helicobacter pylori infections.Trop. Med. Infect. Dis.20238316310.3390/tropicalmed803016336977164
     [Google Scholar]
  9. BurdanF. Rozylo-KalinowskaI. SzumiloJ. ZinkiewiczK. DworzanskiW. KrupskiW. DabrowskiA. Anatomical classification of the shape and topography of the stomach.Surg. Radiol. Anat.201234217117810.1007/s00276‑011‑0893‑822057798
     [Google Scholar]
  10. BurchJ. CollinsB. BurchJ. CollinsB. Anatomy and physiology of the gastrointestinal tract.In: Oxford Handbook of Gastrointestinal NursingOxford University Press202110.1093/med/9780198833178.003.0001
     [Google Scholar]
  11. UzalF.A. PlattnerB.L. HostetterJ.M. Alimentary system.Jubb, Kennedy & Palmer’s Pathology of Domestic Animals201621257.e210.1016/B978‑0‑7020‑5318‑4.00007‑3
     [Google Scholar]
  12. VdoviakováK. PetrovováE. MaloveskáM. KrešákováL. TelekyJ. EliasM.Z.J. PetrášováD. Surgical anatomy of the gastrointestinal tract and its vasculature in the laboratory rat.Gastroenterol. Res. Pract.2016201611110.1155/2016/263236826819602
     [Google Scholar]
  13. MahadevanV. Anatomy of the stomach.Surgery20173560811
     [Google Scholar]
  14. CamilleriM. Integrated upper gastrointestinal response to food intake.Gastroenterology2006131264065810.1053/j.gastro.2006.03.02316890616
     [Google Scholar]
  15. EngevikA.C. KajiI. GoldenringJ.R. The physiology of the gastric parietal cell.Physiol. Rev.2020100257360210.1152/physrev.00016.201931670611
     [Google Scholar]
  16. AgarwalP. BadkurM. AgarwalR. PatelS. Prevalence of Helicobacter pylori infection in upper gastrointestinal tract disorders (dyspepsia) patients visiting outpatient department of a hospital of North India.J. Family Med. Prim. Care20187357758010.4103/jfmpc.jfmpc_213_1730112312
     [Google Scholar]
  17. AhmedM. AhmedS. Functional, diagnostic and therapeutic aspects of gastrointestinal hormones.Gastroenterol. Res.201912523324410.14740/gr121931636773
     [Google Scholar]
  18. RamakrishnanK. SalinasR.C. Peptic ulcer disease.Am. Fam. Physician20077671005101217956071
     [Google Scholar]
  19. AdamsD.H. Sleisenger and fordtran’s gastrointestinal and liver disease.Gut2007568117510.1136/gut.2007.121533
     [Google Scholar]
  20. ChanF.K.L. LeungW.K. Peptic-ulcer disease.Lancet2002360933793394110.1016/S0140‑6736(02)11030‑012354485
     [Google Scholar]
  21. AlakkariA. ZulloA. O’ConnorH.J. Helicobacter pylori and nonmalignant diseases.Helicobacter201116s1Suppl. 1333710.1111/j.1523‑5378.2011.00878.x21896083
     [Google Scholar]
  22. ChungC.S. ChiangT.H. LeeY.C. A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers.Korean J. Intern. Med.201530555957010.3904/kjim.2015.30.5.55926354049
     [Google Scholar]
  23. HewetsonM. TallonR. Equine squamous gastric disease: Prevalence, impact and management.Vet. Med.20211238139910.2147/VMRR.S23525835004264
     [Google Scholar]
  24. TamY.H. LeeK.H. ToK.F. ChanK.W. CheungS.T. Helicobacter pylori-positive versus Helicobacter pylori-negative idiopathic peptic ulcers in children with their long-term outcomes.J. Pediatr. Gastroenterol. Nutr.200948329930510.1097/MPG.0b013e31818c5f8b19274785
     [Google Scholar]
  25. MhaskarR. RicardoI. AzliyatiA. LaxminarayanR. AmolB. SantoshW. BooK. Assessment of risk factors of Helicobacter pylori infection and peptic ulcer disease.J. Glob. Infect. Dis.201352606710.4103/0974‑777X.11228823853433
     [Google Scholar]
  26. MalatyH.M. Epidemiology of Helicobacter pylori infection.Best Pract. Res. Clin. Gastroenterol.200721220521410.1016/j.bpg.2006.10.00517382273
     [Google Scholar]
  27. SungJ.J.Y. KuipersE.J. El-SeragH.B. Systematic review: The global incidence and prevalence of peptic ulcer disease.Aliment. Pharmacol. Ther.200929993894610.1111/j.1365‑2036.2009.03960.x19220208
     [Google Scholar]
  28. HandaO. NaitoY. YoshikawaT. Helicobacter pylori: A ROS-inducing bacterial species in the stomach.Inflamm. Res.20105912997100310.1007/s00011‑010‑0245‑x20820854
     [Google Scholar]
  29. TytgatG.N.J. Etiopathogenetic principles and peptic ulcer disease classification.Dig. Dis.201129545445810.1159/00033152022095009
     [Google Scholar]
  30. ScarpignatoC. HuntR.H. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: Clinical picture, pathogenesis, and prevention.Gastroenterol. Clin. North Am.201039343346410.1016/j.gtc.2010.08.01020951911
     [Google Scholar]
  31. DrinaM. Peptic ulcer disease and non-steroidal anti-inflammatory drugs.Aust. Prescr.2017403919310.18773/austprescr.2017.03728798512
     [Google Scholar]
  32. MelcarneL. García-IglesiasP. CalvetX. Management of NSAID-associated peptic ulcer disease.Expert Rev. Gastroenterol. Hepatol.201610672373310.1586/17474124.2016.114287226775657
     [Google Scholar]
  33. TaiF.W.D. McAlindonM.E. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract.Clin. Med.202121213113410.7861/clinmed.2021‑003933762373
     [Google Scholar]
  34. WallaceJ.L. Pathogenesis of NSAID-induced gastroduodenal mucosal injury.Best Pract. Res. Clin. Gastroenterol.200115569170310.1053/bega.2001.022911566035
     [Google Scholar]
  35. WangB. WuL. ChenJ. DongL. ChenC. WenZ. HuJ. FlemingI. WangD.W. Metabolism pathways of arachidonic acids: Mechanisms and potential therapeutic targets.Signal Transduct. Target. Ther.2021619410.1038/s41392‑020‑00443‑w33637672
     [Google Scholar]
  36. DragstedtL.R. Peptic ulcer.Am. J. Surg.1969117214315610.1016/0002‑9610(69)90298‑05773929
     [Google Scholar]
  37. MalfertheinerP. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer.Dig. Dis.201129545946410.1159/00033221322095010
     [Google Scholar]
  38. CalamJ. BaronJ.H. ABC of the upper gastrointestinal tract: Pathophysiology of duodenal and gastric ulcer and gastric cancer.BMJ2001323731998098210.1136/bmj.323.7319.98011679389
     [Google Scholar]
  39. SiddiquiA.H. FarooqU. SiddiquiF. Curling Ulcer.In: StatPearls: StatPearls Publishing Copyright © 2023.StatPearls Publishing LLC2023
     [Google Scholar]
  40. ZhuH. HartC.A. SalesD. RobertsN.B. Bacterial killing in gastric juice – effect of pH and pepsin on Escherichia coli and Helicobacter pylori.J. Med. Microbiol.20065591265127010.1099/jmm.0.46611‑016914658
     [Google Scholar]
  41. LiL.F. ChanR.L.Y. LuL. ShenJ. ZhangL. WuW.K.K. WangL. HuT. LiM.X. ChoC.H. Cigarette smoking and gastrointestinal diseases: The causal relationship and underlying molecular mechanisms (Review).Int. J. Mol. Med.201434237238010.3892/ijmm.2014.178624859303
     [Google Scholar]
  42. BishehsariF. MagnoE. SwansonG. DesaiV. VoigtR.M. ForsythC.B. KeshavarzianA. Alcohol and gut-derived inflammation.Alcohol Res.201738216317128988571
     [Google Scholar]
  43. BodeC. BodeJ.C. Alcohol’s role in gastrointestinal tract disorders.Alcohol Health Res. World1997211768315706765
     [Google Scholar]
  44. ZhangL. RenJ.W. WongC.C. WuW.K. RenS.X. ShenJ. ChanR.L. ChoC.H. Effects of cigarette smoke and its active components on ulcer formation and healing in the gastrointestinal mucosa.Curr. Med. Chem.2012191636910.2174/09298671280341392622300077
     [Google Scholar]
  45. NehligA. Effects of coffee on the gastro-intestinal tract: A narrative review and literature update.Nutrients202214239910.3390/nu1402039935057580
     [Google Scholar]
  46. RossiR.E. ElveviA. CitterioD. CoppaJ. InvernizziP. MazzaferroV. MassironiS. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.World J. Gastroenterol.202127355890590710.3748/wjg.v27.i35.589034629807
     [Google Scholar]
  47. EpelboymI. MazehH. Zollinger-Ellison syndrome: Classical considerations and current controversies.Oncologist2014191445010.1634/theoncologist.2013‑036924319020
     [Google Scholar]
  48. Badi AlbaqawiA.S. Abo el-FetohN.M. Abdullah AlanaziR.F. Farhan AlanaziN.S. Emad AlrayyaS. Nughaymish Mulfi AlanaziA. Trad AleneziS.Z. Alrkowi AlanaziR.A. Muaddi AlshalanA. Tabaan AleneziO. Bakr AliW.M. Profile of peptic ulcer disease and its risk factors in Arar, Northern Saudi Arabia.Electron. Physician20179115740574510.19082/574029403613
     [Google Scholar]
  49. JagtapA.G. DamleA. VadorN. Vulnerability of gastric mucosa in diabetic rats, its pathogenesis and amelioration by Cuminum cyminum.Indian J. Pharm. Sci.201274538739610.4103/0250‑474X.10841323716866
     [Google Scholar]
  50. OwuD.U. ObembeA.O. NwokochaC.R. EdohoI.E. OsimE.E. Gastric ulceration in diabetes mellitus: Protective role of vitamin C.ISRN Gastroenterol.201220121710.5402/2012/36280522778975
     [Google Scholar]
  51. MalatyH.M. GrahamD.Y. IsakssonI. EngstrandL. PedersenN.L. Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection?Arch. Intern. Med.2000160110510910.1001/archinte.160.1.10510632311
     [Google Scholar]
  52. MiftahussururM. YamaokaY. Helicobacter pylori virulence genes and host genetic polymorphisms as risk factors for peptic ulcer disease.Expert Rev. Gastroenterol. Hepatol.20159121535154710.1586/17474124.2015.109508926470920
     [Google Scholar]
  53. AtrejaA. FuA.Z. SanakaM.R. VargoJ.J. Non-invasive testing for Helicobacter pylori in patients hospitalized with peptic ulcer hemorrhage: A cost-effectiveness analysis.Dig. Dis. Sci.20105551356136310.1007/s10620‑009‑0865‑619582580
     [Google Scholar]
  54. ValdastriP. SimiM. WebsterR.J.III Advanced technologies for gastrointestinal endoscopy.Annu. Rev. Biomed. Eng.201214139742910.1146/annurev‑bioeng‑071811‑15000622655598
     [Google Scholar]
  55. MarinoniC. RibaldoneD.G. RossoC. AstegianoM. CavigliaG.P. Diagnosis of Helicobacter pylori infection: A look into molecular aspects of urea breath test.Minerva Biotecnol.2019313100710.23736/S1120‑4826.19.02555‑2
     [Google Scholar]
  56. SousaC. FerreiraR. SantosS.B. AzevedoN.F. MeloL.D.R. Advances on diagnosis of Helicobacter pylori infections.Crit. Rev. Microbiol.202349667169210.1080/1040841X.2022.212528736264672
     [Google Scholar]
  57. SabbaghP. Mohammadnia-AfrouziM. JavanianM. BabazadehA. KoppoluV. VasigalaV.R. NouriH.R. EbrahimpourS. Diagnostic methods for Helicobacter pylori infection: Ideals, options, and limitations.Eur. J. Clin. Microbiol. Infect. Dis.2019381556610.1007/s10096‑018‑3414‑430414090
     [Google Scholar]
  58. Talebi Bezmin AbadiA. Diagnosis of Helicobacter pylori using invasive and noninvasive approaches.J. Pathogens2018201811310.1155/2018/906495229951318
     [Google Scholar]
  59. PatelS.K. PratapC.B. JainA.K. GulatiA.K. NathG. Diagnosis of Helicobacter pylori: What should be the gold standard?World J. Gastroenterol.20142036128471285910.3748/wjg.v20.i36.1284725278682
     [Google Scholar]
  60. GirdalidzeA.M. ElisabedashviliG.V. SharvadzeL.G. DzhorbenadzeT.A. Comparative diagnostic value of Helicobacter pylori infection testing methods.Georgian Med. News2013225536024423677
     [Google Scholar]
  61. RedéenS. PeterssonF. TörnkrantzE. LevanderH. MårdhE. BorchK. Reliability of diagnostic tests for Helicobacter pylori infection.Gastroenterol. Res. Pract.201120111610.1155/2011/94065021826138
     [Google Scholar]
  62. PengN.J. LaiK.H. LiuR.S. LeeS.C. TsayD.G. LoC.C. TsengH.H. HuangW.K. LoG.H. HsuP.I. Capsule 13 C-urea breath test for the diagnosis of Helicobacter pylori infection.World J. Gastroenterol.20051191361136410.3748/wjg.v11.i9.136115761976
     [Google Scholar]
  63. FerwanaM. AbdulmajeedI. AlhajiahmedA. MadaniW. FirwanaB. HasanR. AltayarO. LimburgP.J. MuradM.H. KnawyB. Accuracy of urea breath test in Helicobacter pylori infection: Meta-analysis.World J. Gastroenterol.20152141305131410.3748/wjg.v21.i4.130525632206
     [Google Scholar]
  64. ShimoyamaT. SawayaM. IshiguroA. HanabataN. YoshimuraT. FukudaS. Applicability of a rapid stool antigen test, using monoclonal antibody to catalase, for the management of Helicobacter pylori infection.J. Gastroenterol.201146448749110.1007/s00535‑011‑0371‑421264478
     [Google Scholar]
  65. KazemiS. TavakkoliH. HabizadehM.R. EmamiM.H. Diagnostic values of Helicobacter pylori diagnostic tests: Stool antigen test, urea breath test, rapid urease test, serology and histology.J. Res. Med. Sci.20111691097110422973378
     [Google Scholar]
  66. ShimoyamaT. Stool antigen tests for the management of Helicobacter pylori infection.World J. Gastroenterol.201319458188819110.3748/wjg.v19.i45.818824363508
     [Google Scholar]
  67. RicciC. HoltonJ. VairaD. Diagnosis of Helicobacter pylori: Invasive and non-invasive tests.Best Pract. Res. Clin. Gastroenterol.200721229931310.1016/j.bpg.2006.11.00217382278
     [Google Scholar]
  68. WangY.K. KuoF.C. LiuC.J. WuM.C. ShihH.Y. WangS.S. WuJ.Y. KuoC.H. HuangY.K. WuD.C. Diagnosis of Helicobacter pylori infection: Current options and developments.World J. Gastroenterol.20152140112211123510.3748/wjg.v21.i40.1122126523098
     [Google Scholar]
  69. GrahamD.Y. KatoM. AsakaM. Gastric endoscopy in the 21st century: Appropriate use of an invasive procedure in the era of non-invasive testing.Dig. Liver Dis.200840749750310.1016/j.dld.2008.02.03218403275
     [Google Scholar]
  70. AtkinsonN.S.S. BradenB. Helicobacter pylori infection: Diagnostic strategies in primary diagnosis and after therapy.Dig. Dis. Sci.2016611192410.1007/s10620‑015‑3877‑426391269
     [Google Scholar]
  71. SunB. LiuJ. LiS. LovellJ.F. ZhangY. Imaging of gastrointestinal tract ailments.J. Imaging20239611510.3390/jimaging906011537367463
     [Google Scholar]
  72. ZulloA. HassanC. CampoS.M.A. MoriniS. Bleeding peptic ulcer in the elderly: Risk factors and prevention strategies.Drugs Aging2007241081582810.2165/00002512‑200724100‑0000317896831
     [Google Scholar]
  73. Di CarloI. ToroA. SparatoreF. PrimoS. BarbagalloF. Di BlasiM. Emergency gastric ulcer complications in elderly. Factors affecting the morbidity and mortality in relation to therapeutic approaches.Minerva Chir.200661432533217122765
     [Google Scholar]
  74. HearnshawS.A. LoganR.F.A. LoweD. TravisS.P.L. MurphyM.F. PalmerK.R. Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: Results of a nationwide audit.Gut20105981022102910.1136/gut.2008.17459920357318
     [Google Scholar]
  75. TsoiK.K.F. HiraiH.W. SungJ.J.Y. Meta-analysis: Comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding.Aliment. Pharmacol. Ther.201338772172810.1111/apt.1244123915096
     [Google Scholar]
  76. CoppolinoF.F. GattaG. Di GreziaG. ReginelliA. IacobellisF. ValloneG. GigantiM. GenoveseE.A. Gastrointestinal perforation: Ultrasonographic diagnosis.Crit. Ultrasound J.20135S1Suppl. 1S410.1186/2036‑7902‑5‑S1‑S423902744
     [Google Scholar]
  77. BertleffM.J.O.E. LangeJ.F. Perforated peptic ulcer disease: A review of history and treatment.Dig. Surg.201027316116910.1159/00026465320571260
     [Google Scholar]
  78. CherianP.T. CherianS. SinghP. Long-term follow-up of patients with gastric outlet obstruction related to peptic ulcer disease treated with endoscopic balloon dilatation and drug therapy.Gastrointest. Endosc.200766349149710.1016/j.gie.2006.11.01617640640
     [Google Scholar]
  79. ChittajalluV. OmarY.A. Simons-LinaresC.R. ChahalP. Endoscopic balloon dilation management for benign duodenal stenosis.Surg. Endosc.20233753610361810.1007/s00464‑022‑09844‑036624215
     [Google Scholar]
  80. TalleyN.J. VakilN. Practice Parameters Committee of the American College of Gastroenterology Guidelines for the management of dyspepsia.Am. J. Gastroenterol.2005100102324233710.1111/j.1572‑0241.2005.00225.x16181387
     [Google Scholar]
  81. ElbehiryA. MarzoukE. AldubaibM. AbalkhailA. AnagreyyahS. AnajirihN. AlmuzainiA.M. RawwayM. AlfadhelA. DrazA. Abu-OkailA. Helicobacter pylori infection: Current status and future prospects on diagnostic, therapeutic and control challenges.Antibiotics202312219110.3390/antibiotics1202019136830102
     [Google Scholar]
  82. FordA.C. GurusamyK.S. DelaneyB. FormanD. MoayyediP. Eradication therapy for peptic ulcer disease in Helicobacter pylori -positive people.Cochrane Libr.201620164CD00384010.1002/14651858.CD003840.pub527092708
     [Google Scholar]
  83. BashirS.K. KhanM.B. Overview of Helicobacter pylori infection, prevalence, risk factors, and its prevention.Adv. Gut Microbiome Res.202320231910.1155/2023/9747027
     [Google Scholar]
  84. Garza-GonzálezE. Perez-PerezG.I. Maldonado-GarzaH.J. Bosques-PadillaF.J. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication.World J. Gastroenterol.20142061438144910.3748/wjg.v20.i6.143824587620
     [Google Scholar]
  85. RobertsL.T. IssaP.P. SinnathambyE.S. GranierM. MayeuxH. EubanksT.N. MaloneK. AhmadzadehS. CornettE.M. ShekoohiS. KayeA.D. Helicobacter pylori: A review of current treatment options in clinical practice.Life20221212203810.3390/life1212203836556402
     [Google Scholar]
  86. GhazzawiI.M. ObeidatW.A. ZuriekatF.A. Triple therapy with pantoprazole, clarithromycin and amoxicillin for eradication in patients with Helicobacter pylori positive duodenal ulcers.Saudi Med. J.20042581006100915322588
     [Google Scholar]
  87. O’MorainN.R. DoreM.P. O’ConnorA.J.P. GisbertJ.P. O’MorainC.A. Treatment of Helicobacter pylori infection in 2018.Helicobacter201823S1Suppl. 1e1251910.1111/hel.1251930203585
     [Google Scholar]
  88. SuerbaumS. CoombsN. PatelL. PschenizaD. RoxK. FalkC. GruberA.D. KershawO. ChhatwalP. BrönstrupM. BilitewskiU. JosenhansC. Identification of antimotilins, novel inhibitors of Helicobacter pylori flagellar motility that inhibit stomach colonization in a mouse model.MBio2022132e03755-2110.1128/mbio.03755‑2135227071
     [Google Scholar]
  89. BranquinhoD. AlmeidaN. GregórioC. CabralJ.E.P. CaselaA. DonatoM.M. ToméL. Levofloxacin or Clarithromycin-based quadruple regimens: What is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?BMC Gastroenterol.20171713110.1186/s12876‑017‑0589‑628202013
     [Google Scholar]
  90. MalfertheinerP. MegraudF. O’MorainC.A. AthertonJ. AxonA.T.R. BazzoliF. GensiniG.F. GisbertJ.P. GrahamD.Y. RokkasT. El-OmarE.M. KuipersE.J. European Helicobacter Study Group Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report.Gut201261564666410.1136/gutjnl‑2012‑30208422491499
     [Google Scholar]
  91. HanS. DengZ. CheungK. LyuT. ChanP. LiY. NiL. LuoX. LiK. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: A three-arm, randomised clinical trial protocol.BMC Gastroenterol.202323123110.1186/s12876‑023‑02872‑737420205
     [Google Scholar]
  92. GisbertJ. CalvetX. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.Clin. Exp. Gastroenterol.20125233410.2147/CEG.S2541922457599
     [Google Scholar]
  93. ShihC.A. ShieC.B. HsuP.I. Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances.Therap. Adv. Gastroenterol.2022151756284822113816810.1177/1756284822113816836458050
     [Google Scholar]
  94. MégraudF. The challenge of Helicobacter pylori resistance to antibiotics: The comeback of bismuth-based quadruple therapy.Therap. Adv. Gastroenterol.20125210310910.1177/1756283X1143249222423259
     [Google Scholar]
  95. YuanY. FordA.C. KhanK.J. GisbertJ.P. FormanD. LeontiadisG.I. TseF. CalvetX. FalloneC. FischbachL. OderdaG. BazzoliF. MoayyediP. Optimum duration of regimens for Helicobacter pylori eradication.Cochrane Database Syst. Rev.201312CD00833724338763
     [Google Scholar]
  96. AlkimH. KoksalA.R. BogaS. SenI. AlkimC. Role of bismuth in the eradication of Helicobacter pylori.Am. J. Ther.2017246e751e75710.1097/MJT.000000000000038926808355
     [Google Scholar]
  97. ButlerM.S. HendersonI.R. CaponR.J. BlaskovichM.A.T. Antibiotics in the clinical pipeline as of December 2022.J. Antibiot. (Tokyo)202376843147310.1038/s41429‑023‑00629‑837291465
     [Google Scholar]
  98. GisbertJ.P. Fernández-BermejoM. Molina-InfanteJ. Pérez-GallardoB. Prieto-BermejoA.B. Mateos-RodríguezJ.M. Robledo-AndrésP. González-GarcíaG. First‐line triple therapy with levofloxacin for Helicobacter pylori eradication.Aliment. Pharmacol. Ther.200726349550010.1111/j.1365‑2036.2007.03384.x17635384
     [Google Scholar]
  99. Mansour-GhanaeiF. MasihipourB. FathalipourM. HassanipourS. SokhanvarH. Mansour-GhanaeiA. AsgharnezhadM. JoukarF. The efficacy, safety, and tolerability of levofloxacin quadruple therapy for Helicobacter pylori eradication: A randomized, double-blind clinical trial.Evid. Based Complement. Alternat. Med.202220221710.1155/2022/979490136523418
     [Google Scholar]
  100. RazavizadehM. ArjA. MollaeiM. MoravejiA. The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication.J. Res. Pharm. Pract.20209210110510.4103/jrpp.JRPP_19_8633102384
     [Google Scholar]
  101. ChenP.Y. WuM.S. ChenC.Y. BairM.J. ChouC.K. LinJ.T. LiouJ.M. Taiwan Gastrointestinal Disease and Helicobacter Consortium Systematic review with meta‐analysis: The efficacy of levofloxacin triple therapy as the first‐ or second‐line treatments of Helicobacter pylori infection.Aliment. Pharmacol. Ther.201644542743710.1111/apt.1371227363687
     [Google Scholar]
  102. StrandD.S. KimD. PeuraD.A. 25 years of proton pump inhibitors: A comprehensive review.Gut Liver2017111273710.5009/gnl1550227840364
     [Google Scholar]
  103. SpechlerS.J. Proton pump inhibitors.Med. Clin. North Am.2019103111410.1016/j.mcna.2018.08.00130466666
     [Google Scholar]
  104. FreedbergD.E. LebwohlB. AbramsJ.A. The impact of proton pump inhibitors on the human gastrointestinal microbiome.Clin. Lab. Med.201434477178510.1016/j.cll.2014.08.00825439276
     [Google Scholar]
  105. LamJ.R. SchneiderJ.L. ZhaoW. CorleyD.A. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.JAMA2013310222435244210.1001/jama.2013.28049024327038
     [Google Scholar]
  106. LamJ.R. SchneiderJ.L. QuesenberryC.P. CorleyD.A. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency.Gastroenterology20171524821829.e110.1053/j.gastro.2016.11.02327890768
     [Google Scholar]
  107. KouE. ZhangX. DongB. WangB. ZhuY. Combination of H1 and H2 histamine receptor antagonists: Current knowledge and perspectives of a classic treatment strategy.Life202414216410.3390/life1402016438398673
     [Google Scholar]
  108. TuskeyA. PeuraD. The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.Arthritis Res. Ther.201315Suppl 3S610.1186/ar417824267478
     [Google Scholar]
  109. GrahamD.Y. GentaR.M. Long-term proton pump inhibitor use and gastrointestinal cancer.Curr. Gastroenterol. Rep.200810654354710.1007/s11894‑008‑0100‑119006608
     [Google Scholar]
  110. HuD.H. WongW.C. ZhouJ.X. LuoJ. CaiS.W. ZhouH. TangH. The correlation between the use of the proton pump inhibitor and the clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer.J. Oncol.2022202211010.1155/2022/100179635855807
     [Google Scholar]
  111. TahaA.S. McCloskeyC. McSkimmingP. McConnachieA. Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): A randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Gastroenterol. Hepatol.20183746947610.1016/S2468‑1253(18)30119‑529754836
     [Google Scholar]
  112. KyawM.H. OtaniK. ChingJ.Y.L. HigashimoriA. KeeK.M. WatanabeT. TseY.K. LeeV. TanigawaT. CheongP.K. SuenB.Y. FujiwaraY. LamK. ArakawaT. ChanF.K.L. Misoprostol heals small bowel ulcers in aspirin users with small bowel bleeding.Gastroenterology2018155410901097.e110.1053/j.gastro.2018.06.05629966612
     [Google Scholar]
  113. OshimaT. MiwaH. Potent potassium-competitive acid blockers: A new era for the treatment of acid-related diseases.J. Neurogastroenterol. Motil.201824333434410.5056/jnm1802929739175
     [Google Scholar]
  114. MizokamiY. OdaK. FunaoN. NishimuraA. SoenS. KawaiT. AshidaK. SuganoK. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: Randomised, lansoprazole-controlled non-inferiority and single-blind extension study.Gut20186761042105110.1136/gutjnl‑2017‑31401028988197
     [Google Scholar]
  115. ChoY.K. ChoiM.G. ChoiS.C. LeeK.M. KimT.O. ParkS.H. MoonJ.S. LimY.J. KangD.H. CheonG.J. BaikG.H. KimK.O. ChoK.B. JangJ.S. ParkJ.J. SonB.K. JungH.K. KimB.W. KimS.K. LeeS.T. ChaJ.M. KimA.R. KimE.J. ParkH.W. SongG.S. Randomised clinical trial: Tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.Aliment. Pharmacol. Ther.202052578979710.1111/apt.1586532701188
     [Google Scholar]
  116. KimH.U. Diagnostic and treatment approaches for refractory peptic ulcers.Clin. Endosc.201548428529010.5946/ce.2015.48.4.28526240800
     [Google Scholar]
  117. TakahashiN. TakeY. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility.J. Pharmacol. Exp. Ther.2018364227528610.1124/jpet.117.24420229180359
     [Google Scholar]
  118. TAP. Gastric outlet obstruction: Clinical presentations and its surgical management.Int Surg J2018526225
     [Google Scholar]
  119. DarmonI. RebiboL. DioufM. ChivotC. RiaultC. YzetT. Le MouelJ.P. RegimbeauJ.M. Management of bleeding peptic duodenal ulcer refractory to endoscopic treatment: Surgery or transcatheter arterial embolization as first-line therapy? A retrospective single-center study and systematic review.Eur. J. Trauma Emerg. Surg.20204651025103510.1007/s00068‑020‑01356‑732246169
     [Google Scholar]
  120. PansaA. KuriharaH. MemonM.A. Updates in laparoscopic surgery for perforated peptic ulcer disease: State of the art and future perspectives.Ann. Laparosc. Endosc. Surg.20205510.21037/ales.2019.11.03
     [Google Scholar]
  121. QuahG.S. EslickG.D. CoxM.R. Laparoscopic repair for perforated peptic ulcer disease has better outcomes than open repair.J. Gastrointest. Surg.201923361862510.1007/s11605‑018‑4047‑830465190
     [Google Scholar]
  122. SpiliopoulosS. InchingoloR. LucatelliP. IezziR. DiamantopoulosA. PosaA. BarryB. RicciC. CiniM. KonstantosC. PalialexisK. ReppasL. TrikolaA. NardellaM. AdamA. BrountzosE. Transcatheter arterial embolization for bleeding peptic ulcers: A multicenter study.Cardiovasc. Intervent. Radiol.20184191333133910.1007/s00270‑018‑1966‑429671058
     [Google Scholar]
  123. PandeyM.M. RastogiS. RawatA.K.S. Indian traditional ayurvedic system of medicine and nutritional supplementation.Evid. Based Complement. Alternat. Med.2013201311210.1155/2013/37632723864888
     [Google Scholar]
  124. TiwariM JoshiR TiwariV Design of novel hybrid secondary metabolite targets to diguanylate cyclase of Acinetobacter baumannii.FEMS Microbes20212xtab017
     [Google Scholar]
  125. VimalaG. Gricilda ShobaF. A review on antiulcer activity of few Indian medicinal plants.Int. J. Microbiol.2014201411410.1155/2014/51959024971094
     [Google Scholar]
  126. RoyA.J. MautC. GogoiH.K. AhmedS.I. KashyapA. A review on herbal drugs used in the treatment of peptic ulcer.Curr. Drug Discov. Technol.2023203e12122221186910.2174/157016382066622121214222136515023
     [Google Scholar]
  127. RavishankarB. ShuklaV.J. Indian systems of medicine: A brief profile.Afr. J. Tradit. Complement. Altern. Med.20084331933710.4314/ajtcam.v4i3.3122620161896
     [Google Scholar]
  128. SchexnaildreD. An Ayurvedic approach to sustaining and pampering the feet of healthcare workers.J. Interprof. Educ. Pract.20222910057610.1016/j.xjep.2022.10057636440089
     [Google Scholar]
  129. AwaadA.S. El-MeligyR.M. SolimanG.A. Natural products in treatment of ulcerative colitis and peptic ulcer.J. Saudi Chem. Soc.201317110112410.1016/j.jscs.2012.03.002
     [Google Scholar]
  130. JaiswalY.S. WilliamsL.L. A glimpse of Ayurveda – The forgotten history and principles of Indian traditional medicine.J. Tradit. Complement. Med.201771505310.1016/j.jtcme.2016.02.00228053888
     [Google Scholar]
  131. YaoR. HeinrichM. ZhangB. WeiX. QiY. GaoW. Single botanical drugs in the Ayurvedic Pharmacopoeia of India—A quantitative ethnobotanical analysis.Front. Pharmacol.202314113644610.3389/fphar.2023.113644637251315
     [Google Scholar]
  132. BeeramS. Efficacy of yoga and naturopathy in the management of gastritis.EJBPS2020712219225
     [Google Scholar]
  133. MyersS.P. VigarV. The state of the evidence for whole-system, multi-modality naturopathic medicine: A systematic scoping review.J. Altern. Complement. Med.201925214116810.1089/acm.2018.034030785315
     [Google Scholar]
  134. KhoderG. Al-MenhaliA.A. Al-YassirF. KaramS.M. Potential role of probiotics in the management of gastric ulcer.Exp. Ther. Med.201612131710.3892/etm.2016.329327347010
     [Google Scholar]
  135. GoderskaK. Agudo PenaS. AlarconT. Helicobacter pylori treatment: Antibiotics or probiotics.Appl. Microbiol. Biotechnol.201810211710.1007/s00253‑017‑8535‑729075827
     [Google Scholar]
  136. HasnaB. HouariH. KoulaD. MarinaS. EmiliaU. AssiaB. In vitro and in vivo study of combined effect of some algerian medicinal plants and probiotics against Helicobacter pylori. Microorganisms2023115124210.3390/microorganisms1105124237317215
     [Google Scholar]
  137. LattimerJ.M. HaubM.D. Effects of dietary fiber and its components on metabolic health.Nutrients20102121266128910.3390/nu212126622254008
     [Google Scholar]
  138. BrunoG. RoccoG. ZaccariP. PorowskaB. MascellinoM.T. SeveriC. Helicobacter pylori infection and gastric dysbiosis: Can probiotics administration be useful to treat this condition?Can. J. Infect. Dis. Med. Microbiol.201820181710.1155/2018/623723930275917
     [Google Scholar]
  139. KulshreshthaM. SrivastavaG. SinghM. Pathophysiological status and nutritional therapy of peptic ulcer: An update.Environ. Dis.2017237610.4103/ed.ed_11_17
     [Google Scholar]
  140. VomeroN.D. ColpoE. Nutritional care in peptic ulcer.Arq. Bras. Cir. Dig.201427429830210.1590/S0102‑6720201400040001725626944
     [Google Scholar]
  141. GuptaM. KapoorB. GuptaR. SinghN. Plants and phytochemicals for treatment of peptic ulcer: An overview.S. Afr. J. Bot.202113810511410.1016/j.sajb.2020.11.030
     [Google Scholar]
  142. LimJ.M. SongC.H. ParkS.J. ParkD.C. JungG.W. ChoH.R. BashirK.M.I. KuS.K. ChoiJ.S. Protective effects of triple fermented barley extract (FBe) on indomethacin-induced gastric mucosal damage in rats.BMC Complement. Altern. Med.20191914910.1186/s12906‑019‑2457‑030786935
     [Google Scholar]
  143. ZhengH.M. ChoiM.J. KimJ.M. ChaK.H. LeeK.W. ParkY.H. HongS.S. LeeD.H. Centella asiatica leaf extract protects against indomethacin-induced gastric mucosal injury in rats.J. Med. Food2016191384610.1089/jmf.2015.346426469560
     [Google Scholar]
  144. AdinorteyM.B. AnsahC. GalyuonI. NyarkoA. In vivo models used for evaluation of potential antigastroduodenal ulcer agents.Ulcers2013201311210.1155/2013/796405
     [Google Scholar]
  145. OkaK. SekiT. AkatsuT. WakabayashiT. InuiK. YoshinoJ. Clinical study using novel endoscopic system for measuring size of gastrointestinal lesion.World J. Gastroenterol.201420144050405810.3748/wjg.v20.i14.405024744595
     [Google Scholar]
  146. MoodyF.G. CheungL.Y. Stress ulcers: Their pathogenesis, diagnosis, and treatment.Surg. Clin. North Am.19765661469147810.1016/S0039‑6109(16)41099‑6793064
     [Google Scholar]
  147. JiaY.T. WeiW. MaB. XuY. LiuW.J. WangY. LvK.Y. TangH.T. WeiD. XiaZ.F. Activation of p38 MAPK by reactive oxygen species is essential in a rat model of stress-induced gastric mucosal injury.J. Immunol.2007179117808781910.4049/jimmunol.179.11.780818025227
     [Google Scholar]
  148. TarnaskyP.R. LivingstonE.H. JacobsK.M. ZimmermanB.J. GuthP.H. GarrickT.R. Role of oxyradicals in cold water immersion restraint-induced gastric mucosal injury in the rat.Dig. Dis. Sci.199035217317710.1007/BF015367592302974
     [Google Scholar]
  149. ZhangY. DuanC. WuS. MaJ. LiuY. LiW. WangT. YangL. ChengK. ZhuangR. Knockout of IL-6 mitigates cold water-immersion restraint stress-induced intestinal epithelial injury and apoptosis.Front. Immunol.20221393668910.3389/fimmu.2022.93668936505466
     [Google Scholar]
  150. ZhaoD.Q. XueH. SunH.J. Nervous mechanisms of restraint water-immersion stress-induced gastric mucosal lesion.World J. Gastroenterol.202026202533254910.3748/wjg.v26.i20.253332523309
     [Google Scholar]
  151. SalisZ. SainsburyA. Association of long-term use of non-steroidal anti-inflammatory drugs with knee osteoarthritis: A prospective multi-cohort study over 4-to-5 years.Sci. Rep.2024141659310.1038/s41598‑024‑56665‑338504099
     [Google Scholar]
  152. PalC. BinduS. DeyS. AlamA. GoyalM. IqbalM.S. MaityP. AdhikariS.S. BandyopadhyayU. Gallic acid prevents nonsteroidal anti-inflammatory drug-induced gastropathy in rat by blocking oxidative stress and apoptosis.Free Radic. Biol. Med.201049225826710.1016/j.freeradbiomed.2010.04.01320406680
     [Google Scholar]
  153. BinduS. MazumderS. BandyopadhyayU. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective.Biochem. Pharmacol.202018011414710.1016/j.bcp.2020.11414732653589
     [Google Scholar]
  154. MonteiroK.M. SpindolaH.M. PossentiA. TintiS.V. RuizA.L.T.G. LongatoG.B. FioritoG.F. MarchettiG.M. ShiozawaL. PiloniB.U. de OliveiraA.C. MiyagawaL.M. CarvalhoJ.E. Characterization of a refinement of the “pylorus ligation” model of rat gastric ulceration resulting in “no pain” and a more specific pharmacological response.J. Pharmacol. Toxicol. Methods201367212112810.1016/j.vascn.2012.09.00223000280
     [Google Scholar]
  155. Al-GabriN. ElnagarG.M. SaghirS.A.M. El-ShaibanyA. AlnomasyS.F. AlthafarZ.M. ElkomyN.M.I.M. ElaasserM.M. AbdohM.S. YosriM. Preliminary study of gastroprotective effect of Aloe perryi and date palm extracts on pyloric ligation-induced gastric ulcer in experimental rats.BioMed Res. Int.2022202211010.1155/2022/924678535111849
     [Google Scholar]
  156. FigueiredoF.F. DamazoA.S. ArunachalamK. SilvaM.J.D. PavanE. LimaJ.C.S. MartinsD.T.O. Evaluation of the gastroprotective and ulcer healing properties by Fridericia chica (Bonpl.) L.G. Lohmann hydroethanolic extract of leaves.J. Ethnopharmacol.202330911633810.1016/j.jep.2023.11633836870462
     [Google Scholar]
  157. DembińskiA. WarzechaZ. CeranowiczP. BrzozowskiT. DembińskiM. KonturekS.J. PawlikW.W. Role of capsaicin-sensitive nerves and histamine H1, H2, and H3 receptors in the gastroprotective effect of histamine against stress ulcers in rats.Eur. J. Pharmacol.20055081-321122110.1016/j.ejphar.2004.11.05915680274
     [Google Scholar]
  158. SrivastavaV. ViswanathaswamyA.H.M. MohanG. Determination of the antiulcer properties of sodium cromoglycate in pylorus-ligated albino rats.Indian J. Pharmacol.201042318518810.4103/0253‑7613.6684420871772
     [Google Scholar]
  159. RahimN.A. HassandarvishP. GolbabapourS. IsmailS. TayyabS. AbdullaM.A. Gastroprotective effect of ethanolic extract of Curcuma xanthorrhiza leaf against ethanol-induced gastric mucosal lesions in Sprague-Dawley rats.BioMed Res. Int.2014201411010.1155/2014/41640924783203
     [Google Scholar]
  160. ShareefS.H. Al-MedhtiyM.H. IbrahimI.A.A. AlzahraniA.R. JabbarA.A. GalaliY. AghaN.F.S. AzizP.Y. ThabitM.A. AghaD.N.F. SalehenN.A. AmeenZ.M. AbdullaM.A. Gastroprophylactic effects of p-cymene in ethanol-induced gastric ulcer in rats.Processes2022107131410.3390/pr10071314
     [Google Scholar]
  161. ShamsS.G.E. EissaR.G. Amelioration of ethanol-induced gastric ulcer in rats by quercetin: Implication of Nrf2/HO1 and HMGB1/TLR4/NF-κB pathways.Heliyon2022810e1115910.1016/j.heliyon.2022.e1115936311358
     [Google Scholar]
  162. RahmanZ. DwivediD.K. JenaG.B. Ethanol-induced gastric ulcer in rats and intervention of tert-butylhydroquinone: Involvement of Nrf2/HO-1 signalling pathway.Hum. Exp. Toxicol.202039454756210.1177/096032711989555931876185
     [Google Scholar]
  163. RaishM. ShahidM. Bin JardanY.A. AnsariM.A. AlkharfyK.M. AhadA. AbdelrahmanI.A. AhmadA. Al-JenoobiF.I. Gastroprotective effect of sinapic acid on ethanol-induced gastric ulcers in rats: Involvement of Nrf2/HO-1 and NF-κb signaling and antiapoptotic role.Front. Pharmacol.20211262281510.3389/fphar.2021.62281533716749
     [Google Scholar]
  164. OkabeS. AmagaseK. An overview of acetic acid ulcer models--the history and state of the art of peptic ulcer research.Biol. Pharm. Bull.20052881321134110.1248/bpb.28.132116079471
     [Google Scholar]
  165. HanT. TangY. LiJ. XueB. GongL. LiJ. YuX. LiuC. Nitric oxide donor protects against acetic acid-induced gastric ulcer in rats via S-nitrosylation of TRPV1 on vagus nerve.Sci. Rep.201771206310.1038/s41598‑017‑02275‑128522805
     [Google Scholar]
  166. KeshavarziZ. ShahrokhiN. KhaksariM. Ulcer healing activity of Mumijo aqueous extract against acetic acid induced gastric ulcer in rats.J. Pharm. Bioallied Sci.201571565910.4103/0975‑7406.14873925709338
     [Google Scholar]
  167. TakeuchiK. Pathogenesis of NSAID-induced gastric damage: Importance of cyclooxygenase inhibition and gastric hypermotility.World J. Gastroenterol.201218182147216010.3748/wjg.v18.i18.214722611307
     [Google Scholar]
  168. FengY. DaiW. KeJ. CuiY. LiS. MaJ. GuoW. ChenG. LiN. LiY. Protective effect of valerian extract capsule (VEC) on ethanol- and indomethacin-induced gastric mucosa injury and ameliorative effect of VEC on gastrointestinal motility disorder.Pharm. Biol.20226011095110510.1080/13880209.2022.207144935658820
     [Google Scholar]
  169. MaX. LuG. SongS. LiuW. WenZ. ZhengX. LüQ. SuD. The features of reserpine-induced gastric mucosal lesions.Acta Pharmacol. Sin.201031893894310.1038/aps.2010.7420686519
     [Google Scholar]
  170. SongJ.L. ZhuK. FengX. ZhaoX. Protective effect Malus pumila Mill leaf polyphenols in reserpine-induced gastric ulcer in mice.J. Korean Soc. Appl. Biol. Chem.201558224925610.1007/s13765‑015‑0021‑2
     [Google Scholar]
  171. KunaL. JakabJ. SmolicR. Raguz-LucicN. VcevA. SmolicM. Peptic ulcer disease: A brief review of conventional therapy and herbal treatment options.J. Clin. Med.20198217910.3390/jcm802017930717467
     [Google Scholar]
  172. UmreR. GaneshpurkarA. GaneshpurkarA. PandeyS. PandeyV. ShrivastavaA. DubeyN. In vitro, in vivo and in silico antiulcer activity of ferulic acid.Future J. Pharm. Sci.20184224825310.1016/j.fjps.2018.08.001
     [Google Scholar]
  173. KhanM.S. AroraP. KalraN. AroraN. In vivo and in vitro animal models for ulcer: A conscious review.J. Drug Deliv. Ther.202212622723110.22270/jddt.v12i6.5690
     [Google Scholar]
  174. KhandareB. KshirsagarS. BhujbalN. In-vitro Gastric acid percent neutralizing potential of household remedies verses marketed antacid preparation: A case report.J. Drug Deliv. Ther.201994-s59559710.22270/jddt.v9i4‑s.3271
     [Google Scholar]
  175. PandaV. ShindeP. DeoraJ. GuptaP. A comparative study of the antacid effect of some commonly consumed foods for hyperacidity in an artificial stomach model.Complement. Ther. Med.20173411111510.1016/j.ctim.2017.08.00228917362
     [Google Scholar]
  176. LirazanM. Jesselyn CuaS. Russelle AlvarezM. In vitro antacid screening of the aqueous and ethanolic leaf extracts of Triticum aestivum (Linn.) and Hordeum vulgare (Linn.).Orient. J. Chem.2018341939910.13005/ojc/340110
     [Google Scholar]
  177. YafoutM. ElhorrH. OtmaniI.S.E. KhayatiY. Evaluation of the acid-neutralizing capacity and other properties of antacids marketed in Morocco.Med. Pharm. Rep.2022951808735720246
     [Google Scholar]
  178. VoropaievM. NockD. Onset of acid-neutralizing action of a calcium/magnesium carbonate-based antacid using an artificial stomach model: An in vitro evaluation.BMC Gastroenterol.202121111210.1186/s12876‑021‑01687‑833676393
     [Google Scholar]
  179. RamanaV. A comparative evaluation of in vitro antacid activity of two Tephrosia species using modified artificial stomach model.Hygeia J. D. Med.2015172917
     [Google Scholar]
  180. RaiG. YadavP. GaneshpurkarA. In vitro H+-K+ ATPase inhibitory potential of methanolic extract of Cissus quadrangularis Linn.Pharmacognosy Res.20124212312610.4103/0974‑8490.9473822518085
     [Google Scholar]
  181. Jaber HoushiaO. AbuEidM. ZaidO. ZaidM. Al-daqqaN. Assessment of the value of the antacid contents of selected Palestinian plants.Am. J. Chem.20132632232510.5923/j.chemistry.20120206.05
     [Google Scholar]
  182. ZhangQ. HuangN. WangJ. LuoH. HeH. DingM. DengW.Q. ZouK. The H+/K+-ATPase inhibitory activities of Trametenolic acid B from Trametes lactinea (Berk.) Pat, and its effects on gastric cancer cells.Fitoterapia20138921021710.1016/j.fitote.2013.05.02123742858
     [Google Scholar]
  183. CumminsG. CoxB.F. CiutiG. AnbarasanT. DesmulliezM.P.Y. CochranS. SteeleR. PlevrisJ.N. KoulaouzidisA. Gastrointestinal diagnosis using non-white light imaging capsule endoscopy.Nat. Rev. Gastroenterol. Hepatol.201916742944710.1038/s41575‑019‑0140‑z30988520
     [Google Scholar]
  184. PrasadS. TyagiA.K. AggarwalB.B. Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.Exp. Biol. Med.2016241878379910.1177/153537021663877027013544
     [Google Scholar]
  185. KumarR. KhanF.U. SharmaA. AzizI.B.A. PoddarN.K. Recent applications of artificial intelligence in the detection of gastrointestinal, hepatic and pancreatic diseases.Curr. Med. Chem.2022291668510.2174/092986732866621040511493833820515
     [Google Scholar]
  186. JiangN. TansukawatN.D. Gonzalez-MaciaL. AtesH.C. DincerC. GüderF. TasogluS. YetisenA.K. Low-cost optical assays for point-of-care diagnosis in resource-limited settings.ACS Sens.2021662108212410.1021/acssensors.1c0066934076428
     [Google Scholar]
  187. DoytchinovaI.A. TaylorP. FlowerD.R. Proteomics in vaccinology and immunobiology: An informatics perspective of the immunone.J. Biomed. Biotechnol.20032003526729014688414
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128310979240828102727
Loading
Unravelling Peptic Ulcers: Comprehensive Insights into Etiology, Diagnosis, Screening Techniques, and Treatment
Curr. Pharm. Des. 31, 2065 (2025); https://doi.org/10.2174/0113816128310979240828102727
/content/journals/cpd/10.2174/0113816128310979240828102727
/content/journals/cpd/10.2174/0113816128310979240828102727
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): epidemiology; Helicobacter pylori; inhibators; peptic ulcer; screening techniques; Ulcer models

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test